Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
64 PLN | -0.47% | -1.39% | -28.89% |
May. 29 | Bioceltix S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 26 | Bioceltix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Capitalization 1 | 171.6 | 133 | 371.7 |
Enterprise Value (EV) 1 | 166 | 129.2 | 362.5 |
P/E ratio | -37.5 x | -14.5 x | -25.8 x |
Yield | - | - | - |
Capitalization / Revenue | - | - | - |
EV / Revenue | - | - | - |
EV / EBITDA | -41.2 x | -15.2 x | -26.7 x |
EV / FCF | - | -20,292,503 x | -40,767,506 x |
FCF Yield | - | -0% | -0% |
Price to Book | 28.6 x | 25.8 x | 35.5 x |
Nbr of stocks (in thousands) | 3,287 | 3,427 | 4,129 |
Reference price 2 | 52.20 | 38.80 | 90.00 |
Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales | - | - | - |
EBITDA 1 | -4.027 | -8.51 | -13.58 |
EBIT 1 | -4.404 | -8.955 | -14.02 |
Operating Margin | - | - | - |
Earnings before Tax (EBT) 1 | -4.356 | -8.967 | -13.69 |
Net income 1 | -4.398 | -8.921 | -13.69 |
Net margin | - | - | - |
EPS 2 | -1.391 | -2.674 | -3.493 |
Free Cash Flow | - | -6.365 | -8.892 |
FCF margin | - | - | - |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | - | - | - |
Net Cash position 1 | 5.52 | 3.83 | 9.14 |
Leverage (Debt/EBITDA) | - | - | - |
Free Cash Flow | - | -6.36 | -8.89 |
ROE (net income / shareholders' equity) | - | -160% | -175% |
ROA (Net income/ Total Assets) | - | -70.6% | -85.9% |
Assets 1 | - | 12.63 | 15.93 |
Book Value Per Share 2 | 1.820 | 1.500 | 2.530 |
Cash Flow per Share 2 | 1.840 | 1.200 | 2.250 |
Capex 1 | 0.01 | 0.35 | 0.46 |
Capex / Sales | - | - | - |
Announcement Date | 5/2/23 | 5/2/23 | 4/26/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-28.56% | 67.09M | |
-12.91% | 78.43B | |
+22.15% | 8.99B | |
+25.50% | 3.72B | |
-2.50% | 3.19B | |
+12.67% | 1.67B | |
-25.16% | 1.24B | |
-27.23% | 1.22B | |
-18.50% | 1.07B | |
-7.57% | 968M |
- Stock Market
- Equities
- BCX Stock
- Financials Bioceltix S.A.